R-Pharm US LLC (RPharm)

Oncology Corporate Profile

HQ Location

P.O. Box 3096
08543
Princeton, NJ

Company Description

R-PHARM US was founded in 2014 with the goal of acquiring and commercializing products that help patients suffering from cancer and immunology conditions. R-PHARM's portfolio includes IXEMPRA, a chemotherapy agent approved for metastatic breast cancer, and a pipeline that includes molecules being developed for immunology and oncology indications.

Website: http://www.rpharm-us.com

Brand Generic Indication
Ixempra_? ixabepiloneIXEMPRA (ixabepilone), a microtubule inhibitor, in combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.



IXEMPRA as monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, andcapecitabine.

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RPH 203RANKL inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.rpharm-us.com

Recent News Headlines

There are no news items to display